



Congestive Heart Failure (CHF)

Questions for Deliberation: October 29, 2015 Public Meeting

Entresto

1. For patients with Class II-IV levels of CHF, is the evidence adequate to demonstrate that the net health benefit of **Entresto** is greater than that of **usual care with ACE inhibitors**?
Yes No
2. Given the available evidence for patients with Class II-IV CHF, what is the care value of **Entresto** vs. **usual care with ACE inhibitors**?
a. Low b. Intermediate c. High
3. Given the available evidence for patients with Class II-IV CHF, what is the provisional health system value of **Entresto**?
a. Low b. Intermediate c. High

CardioMEMS

4. For patients with Class III CHF and a prior hospitalization in the prior 12 months, is the evidence adequate to demonstrate that the net health benefit of **CardioMEMS** is greater than **usual care**?
Yes No
5. Given the available evidence for patients with Class III CHF and a prior hospitalization in the prior 12 months, what is the care value of **CardioMEMS** vs. **usual care**?
a. Low b. Intermediate c. High
6. Given the available evidence for patients with Class III CHF and a prior hospitalization in the prior 12 months, what is the provisional health system value of incorporating **CardioMEMS**?
a. Low b. Intermediate c. High